The Role of Mast Cells in the Induction and Maintenance of Inflammation in Selected Skin Diseases

Ewelina Woźniak, Agnieszka Owczarczyk-Saczonek, Magdalena Lange, Justyna Czarny, Ewa Wygonowska, Waldemar Placek, Bogusław Nedoszytko, Ewelina Woźniak, Agnieszka Owczarczyk-Saczonek, Magdalena Lange, Justyna Czarny, Ewa Wygonowska, Waldemar Placek, Bogusław Nedoszytko

Abstract

Under physiological conditions, skin mast cells play an important role as guardians that quickly react to stimuli that disturb homeostasis. These cells efficiently support, fight infection, and heal the injured tissue. The substances secreted by mast cells allow for communication inside the body, including the immune, nervous, and blood systems. Pathologically non-cancerous mast cells participate in allergic processes but also may promote the development of autoinflammatory or neoplastic disease. In this article, we review the current literature regarding the role of mast cells in autoinflammatory, allergic, neoplastic skin disease, as well as the importance of these cells in systemic diseases with a pronounced course with skin symptoms.

Keywords: Ehlers–Danlos syndrome; Kounis syndrome; allergic contact dermatitis; atopic dermatitis; cutaneous mastocytosis; mast cell activation; mast cell activation syndrome; pseudoallergy; psoriasis; red man syndrome; rosacea; urticaria.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Activity of MCs [26,27,28].

References

    1. Doulatov S., Notta F., Laurenti E., Dick J.E. Hematopoiesis: A Human Perspective. Cell Stem Cell. 2012;10:120–136. doi: 10.1016/j.stem.2012.01.006.
    1. Dahlin J.S., Malinovschi A., Öhrvik H., Sandelin M., Janson C., Alving K., Hallgren J. Lin− CD34hi CD117int/Hi FcεRI+ Cells in Human Blood Constitute a Rare Population of Mast Cell Progenitors. Blood. 2016;127:383–391. doi: 10.1182/blood-2015-06-650648.
    1. Grootens J., Ungerstedt J.S., Nilsson G., Dahlin J.S. Deciphering the Differentiation Trajectory from Hematopoietic Stem Cells to Mast Cells. Blood Adv. 2018;2:2273–2281. doi: 10.1182/bloodadvances.2018019539.
    1. Kounis N.G., Koniari I., Velissaris D., Tzanis G., Hahalis G. Kounis Syndrome—Not a Single-Organ Arterial Disorder but a Multisystem and Multidisciplinary Disease. Balk. Med. J. 2019;36:212. doi: 10.4274/balkanmedj.galenos.2019.2019.5.62.
    1. Fong M., Crane J.S. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Histology, Mast Cells.
    1. Elieh Ali Komi D., Wöhrl S., Bielory L. Mast Cell Biology at Molecular Level: A Comprehensive Review. Clinic. Rev. Allergy Immunol. 2020;58:342–365. doi: 10.1007/s12016-019-08769-2.
    1. Dahlin J.S., Maurer M., Metcalfe D.D., Pejler G., Sagi-Eisenberg R., Nilsson G. The Ingenious Mast Cell: Contemporary Insights into Mast Cell Behavior and Function. Allergy. 2022;77:83–99. doi: 10.1111/all.14881.
    1. Caughey G.H. Mast Cell Tryptases and Chymases in Inflammation and Host Defense. Immunol. Rev. 2007;217:141–154. doi: 10.1111/j.1600-065X.2007.00509.x.
    1. Gonzalez-Quintela A., Vizcaino L., Gude F., Rey J., Meijide L., Fernandez-Merino C., Linneberg A., Vidal C. Factors Influencing Serum Total Tryptase Concentrations in a General Adult Population. Clin. Chem. Lab. Med. 2010;48:701–706. doi: 10.1515/CCLM.2010.124.
    1. Fellinger C., Hemmer W., Wöhrl S., Sesztak-Greinecker G., Jarisch R., Wantke F. Clinical Characteristics and Risk Profile of Patients with Elevated Baseline Serum Tryptase. Allergol. Immunopathol. 2014;42:544–552. doi: 10.1016/j.aller.2014.05.002.
    1. Lyons J.J. Hereditary Alpha Tryptasemia. Immunol. Allergy Clin. N. Am. 2018;38:483–495. doi: 10.1016/j.iac.2018.04.003.
    1. Nguyen A.V., Soulika A.M. The Dynamics of the Skin’s Immune System. Int. J. Mol. Sci. 2019;20:1811. doi: 10.3390/ijms20081811.
    1. Mast Cells as Regulators of Skin Inflammation and Immunity. [(accessed on 13 November 2022)]. Available online: .
    1. Zhao W., Kepley C.L., Morel P.A., Okumoto L.M., Fukuoka Y., Schwartz L.B. FcγRIIa, Not FcγRIIb, Is Constitutively and Functionally Expressed on Skin-Derived Human Mast Cells. J. Immunol. 2006;177:694–701. doi: 10.4049/jimmunol.177.1.694.
    1. Tkaczyk C., Okayama Y., Woolhiser M.R., Hagaman D.D., Gilfillan A.M., Metcalfe D.D. Activation of Human Mast Cells through the High Affinity IgG Receptor. Mol. Immunol. 2002;38:1289–1293. doi: 10.1016/S0161-5890(02)00077-9.
    1. Theoharides T.C., Kalogeromitros D. The Critical Role of Mast Cells in Allergy and Inflammation. Ann. N. Y. Acad. Sci. 2006;1088:78–99. doi: 10.1196/annals.1366.025.
    1. Toyoda M., Makino T., Kagoura M., Morohashi M. Immunolocalization of Substance P in Human Skin Mast Cells. Arch. Dermatol. Res. 2000;292:418–421. doi: 10.1007/s004030000149.
    1. Ødum L., Petersen L.J., Skov P.S., Ebskov L.B. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Is Localized in Human Dermal Neurons and Causes Histamine Release from Skin Mast Cells. Inflamm. Res. 1998;47:488–492. doi: 10.1007/s000110050363.
    1. Xiang Z., Nilsson G. IgE Receptor-Mediated Release of Nerve Growth Factor by Mast Cells: IgE Receptor-Mediated Release of NGF. Clin. Exp. Allergy. 2000;30:1379–1386. doi: 10.1046/j.1365-2222.2000.00906.x.
    1. Siiskonen H., Harvima I. Mast Cells and Sensory Nerves Contribute to Neurogenic Inflammation and Pruritus in Chronic Skin Inflammation. Front. Cell. Neurosci. 2019;13:422. doi: 10.3389/fncel.2019.00422.
    1. Kulka M., Sheen C.H., Tancowny B.P., Grammer L.C., Schleimer R.P. Neuropeptides Activate Human Mast Cell Degranulation and Chemokine Production. Immunology. 2008;123:398–410. doi: 10.1111/j.1365-2567.2007.02705.x.
    1. Cao J., Papadopoulou N., Kempuraj D., Boucher W.S., Sugimoto K., Cetrulo C.L., Theoharides T.C. Human Mast Cells Express Corticotropin-Releasing Hormone (CRH) Receptors and CRH Leads to Selective Secretion of Vascular Endothelial Growth Factor. J. Immunol. 2005;174:7665–7675. doi: 10.4049/jimmunol.174.12.7665.
    1. Alysandratos K., Asadi S., Angelidou A., Zhang B., Sismanopoulos N., Yang H., Critchfield A., Theoharides T.C. Neurotensin and CRH Interactions Augment Human Mast Cell Activation. PLoS ONE. 2012;7:e48934. doi: 10.1371/journal.pone.0048934.
    1. Kounis N.G. Kounis Syndrome (Allergic Angina and Allergic Myocardial Infarction): A Natural Paradigm? Int. J. Cardiol. 2006;110:7–14. doi: 10.1016/j.ijcard.2005.08.007.
    1. Hara M., Ono K., Wada H., Sasayama S., Matsumori A. Preformed Angiotensin II Is Present in Human Mast Cells.6. Cardiovasc Drugs Ther. 2004;18:420.
    1. Cookson H., Grattan C. An Update on Mast Cell Disorders. Clin. Med. 2016;16:580–583. doi: 10.7861/clinmedicine.16-6-580.
    1. Patel N., Mohammadi A., Rhatigan R. A Comparative Analysis of Mast Cell Quantification in Five Common Dermatoses: Lichen Simplex Chronicus, Psoriasis, Lichen Planus, Lupus, and Insect Bite/Allergic Contact Dermatitis/Nummular Dermatitis. ISRN Dermatol. 2012;2012:759630. doi: 10.5402/2012/759630.
    1. Porebski G., Kwiecien K., Pawica M., Kwitniewski M. Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions. Front. Immunol. 2018;9:3027. doi: 10.3389/fimmu.2018.03027.
    1. Valent P., Hartmann K., Bonadonna P., Niedoszytko M., Triggiani M., Arock M., Brockow K. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022. Int. Arch. Allergy Immunol. 2022;183:693–705. doi: 10.1159/000524532.
    1. Omraninava M., Eslami M.M., Aslani S., Razi B., Imani D., Feyzinia S. Interleukin 13 Gene Polymorphism and Susceptibility to Asthma: A Meta-Regression and Meta-Analysis. Eur. Ann. Allergy Clin. Immunol. 2022;54:150. doi: 10.23822/EurAnnACI.1764-1489.180.
    1. Chatila T.A. Interleukin-4 Receptor Signaling Pathways in Asthma Pathogenesis. Trends Mol. Med. 2004;10:493–499. doi: 10.1016/j.molmed.2004.08.004.
    1. Kim S.-H., Ye Y.-M., Palikhe N.S., Kim J.-E., Park H.-S. Genetic and Ethnic Risk Factors Associated with Drug Hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 2010;10:280–290. doi: 10.1097/ACI.0b013e32833b1eb3.
    1. Rausz E., Szilágyi A., Nedoszytko B., Lange M., Niedoszytko M., Lautner-Csorba O., Falus A., Aladzsity I., Kokai M., Valent P., et al. Comparative Analysis of IL6 and IL6 Receptor Gene Polymorphisms in Mastocytosis. Br. J. Haematol. 2013;160:216–219. doi: 10.1111/bjh.12086.
    1. Nedoszytko B., Niedoszytko M., Lange M., van Doormaal J., Gleń J., Zabłotna M., Renke J., Vales A., Buljubasic F., Jassem E., et al. Interleukin-13 Promoter Gene Polymorphism -1112C/T Is Associated with the Systemic Form of Mastocytosis. Allergy. 2009;64:287–294. doi: 10.1111/j.1398-9995.2008.01827.x.
    1. Grootens J., Ungerstedt J.S., Ekoff M., Rönnberg E., Klimkowska M., Amini R.-M., Arock M., Söderlund S., Mattsson M., Nilsson G., et al. Single-Cell Analysis Reveals the KIT D816V Mutation in Haematopoietic Stem and Progenitor Cells in Systemic Mastocytosis. EBioMedicine. 2019;43:150–158. doi: 10.1016/j.ebiom.2019.03.089.
    1. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y. Identification of Mutations in the Coding Sequence of the Proto-Oncogene c-Kit in a Human Mast Cell Leukemia Cell Line Causing Ligand-Independent Activation of c-Kit Product. J. Clin. Investig. 1993;92:1736–1744. doi: 10.1172/JCI116761.
    1. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., Sanchez M.L., Nunez R., Prados A., Aldanondo I., Sanchez L., Dominguez M., Botana L.M., et al. KIT Mutation in Mast Cells and Other Bone Marrow Hematopoietic Cell Lineages in Systemic Mast Cell Disorders: A Prospective Study of the Spanish Network on Mastocytosis (REMA) in a Series of 113 Patients. Blood. 2006;108:2366–2372. doi: 10.1182/blood-2006-04-015545.
    1. Varney V.A., Nicholas A., Warner A., Sumar N. IgE-Mediated Systemic Anaphylaxis And Its Association with Gene Polymorphisms Of ACE, Angiotensinogen And Chymase. JAA. 2019;12:343–361. doi: 10.2147/JAA.S213016.
    1. Theoharides T.C., Valent P., Akin C. Mast Cells, Mastocytosis, and Related Disorders. N. Engl. J. Med. 2015;373:163–172. doi: 10.1056/NEJMra1409760.
    1. Valent P., Akin C., Arock M., Brockow K., Butterfield J.H., Carter M.C., Castells M., Escribano L., Hartmann K., Lieberman P., et al. Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. Int. Arch. Allergy Immunol. 2012;157:215–225. doi: 10.1159/000328760.
    1. Niedoszytko M., Ratajska M., Chełmińska M., Makowiecki M., Malek E., Siemińska A., Limon J., Jassem E. The Angiotensinogen AGT p.M235T Gene Polymorphism May Be Responsible for the Development of Severe Anaphylactic Reactions to Insect Venom Allergens. Int. Arch. Allergy Immunol. 2010;153:166–172. doi: 10.1159/000312634.
    1. Lyons J.J., Chovanec J., O’Connell M.P., Liu Y., Šelb J., Zanotti R., Bai Y., Kim J., Le Q.T., DiMaggio T., et al. Heritable Risk for Severe Anaphylaxis Associated with Increased α-Tryptase–Encoding Germline Copy Number at TPSAB1. J. Allergy Clin. Immunol. 2021;147:622–632. doi: 10.1016/j.jaci.2020.06.035.
    1. Greiner G., Sprinzl B., Górska A., Ratzinger F., Gurbisz M., Witzeneder N., Schmetterer K.G., Gisslinger B., Uyanik G., Hadzijusufovic E., et al. Hereditary α Tryptasemia Is a Valid Genetic Biomarker for Severe Mediator-Related Symptoms in Mastocytosis. Blood. 2021;137:238–247. doi: 10.1182/blood.2020006157.
    1. Jarkvist J., Brockow K., Gülen T. Low Frequency of IgE-Mediated Food Hypersensitivity in Mastocytosis. J. Allergy Clin. Immunol. Pract. 2020;8:3093–3101. doi: 10.1016/j.jaip.2020.05.044.
    1. Choi I.S., Koh Y.I., Chung S.-W., Lim H. Increased Releasability of Skin Mast Cells after Exercise in Patients with Exercise-Induced Asthma. J. Korean Med. Sci. 2004;19:724. doi: 10.3346/jkms.2004.19.5.724.
    1. Carter M.C., Metcalfe D.D., Matito A., Escribano L., Butterfield J.H., Schwartz L.B., Bonadonna P., Zanotti R., Triggiani M., Castells M., et al. Adverse Reactions to Drugs and Biologics in Patients with Clonal Mast Cell Disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. J. Allergy Clin. Immunol. 2019;143:880–893. doi: 10.1016/j.jaci.2018.10.063.
    1. Picard M., Giavina-Bianchi P., Mezzano V., Castells M. Expanding Spectrum of Mast Cell Activation Disorders: Monoclonal and Idiopathic Mast Cell Activation Syndromes. Clin. Ther. 2013;35:548–562. doi: 10.1016/j.clinthera.2013.04.001.
    1. Alvarez-Twose I., González-de-Olano D., Sánchez-Muñoz L., Matito A., Jara-Acevedo M., Teodosio C., García-Montero A., Morgado J.M., Orfao A., Escribano L. Validation of the REMA Score for Predicting Mast Cell Clonality and Systemic Mastocytosis in Patients with Systemic Mast Cell Activation Symptoms. Int. Arch. Allergy Immunol. 2012;157:275–280. doi: 10.1159/000329856.
    1. Hamilton M.J., Scarlata K. Mast Cell Activation Syndrome—What It Is and Isn’t. Pract. Gastroenterol. 2020;7:26–32.
    1. Cardet J.-C., Castells M.C., Hamilton M.J. Immunology and Clinical Manifestations of Non-Clonal Mast Cell Activation Syndrome. Curr. Allergy Asthma Rep. 2013;13:10–18. doi: 10.1007/s11882-012-0326-8.
    1. Galli S.J., Gaudenzio N., Tsai M. Mast Cells in Inflammation and Disease: Recent Progress and Ongoing Concerns. Annu. Rev. Immunol. 2020;38:49–77. doi: 10.1146/annurev-immunol-071719-094903.
    1. Le Q.T., Lyons J.J., Naranjo A.N., Olivera A., Lazarus R.A., Metcalfe D.D., Milner J.D., Schwartz L.B. Impact of Naturally Forming Human α/β-Tryptase Heterotetramers in the Pathogenesis of Hereditary α-Tryptasemia. J. Exp. Med. 2019;216:2348–2361. doi: 10.1084/jem.20190701.
    1. Naranjo A.N., Bandara G., Bai Y., Smelkinson M.G., Tobío A., Komarow H.D., Boyden S.E., Kastner D.L., Metcalfe D.D., Olivera A. Critical signaling events in the mechanoactivation of human mast cells through p. C492Y-ADGRE2. J. Investig. Dermatol. 2020;140:2210–2220.e5. doi: 10.1016/j.jid.2020.03.936.
    1. Valent P., Akin C., Hartmann K., Nilsson G., Reiter A., Hermine O., Sotlar K., Sperr W.R., Escribano L., George T.I., et al. Mast Cells as a Unique Hematopoietic Lineage and Cell System: From Paul Ehrlich’s Visions to Precision Medicine Concepts. Theranostics. 2020;10:10743–10768. doi: 10.7150/thno.46719.
    1. Brockow K., Jofer C., Behrendt H., Ring J. Anaphylaxis in Patients with Mastocytosis: A Study on History, Clinical Features and Risk Factors in 120 Patients: Anaphylaxis in Patients with Mastocytosis. Allergy. 2008;63:226–232. doi: 10.1111/j.1398-9995.2007.01569.x.
    1. Akin C., Valent P., Metcalfe D.D. Mast Cell Activation Syndrome: Proposed Diagnostic Criteria. J. Allergy Clin. Immunol. 2010;126:1099–1104.e4. doi: 10.1016/j.jaci.2010.08.035.
    1. Valent P. Mast Cell Activation Syndromes: Definition and Classification. Allergy. 2013;68:417–424. doi: 10.1111/all.12126.
    1. Valent P., Akin C., Bonadonna P., Hartmann K., Brockow K., Niedoszytko M., Nedoszytko B., Siebenhaar F., Sperr W.R., Elberink J.N.G.O., et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (MCAS) J. Allergy Clin. Immunol. Pract. 2019;7:1125–1133.e1. doi: 10.1016/j.jaip.2019.01.006.
    1. Valent P., Akin C., Nedoszytko B., Bonadonna P., Hartmann K., Niedoszytko M., Brockow K., Siebenhaar F., Triggiani M., Arock M., et al. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int. J. Mol. Sci. 2020;21:9030. doi: 10.3390/ijms21239030.
    1. Walker M.E., Hatfield J.K., Brown M.A. New Insights into the Role of Mast Cells in Autoimmunity: Evidence for a Common Mechanism of Action? Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2012;1822:57–65. doi: 10.1016/j.bbadis.2011.02.009.
    1. Ramos-Casals M., Brito-Zerón P., López-Guillermo A., Khamashta M.A., Bosch X. Adult Haemophagocytic Syndrome. Lancet. 2014;383:1503–1516. doi: 10.1016/S0140-6736(13)61048-X.
    1. Sandler R.D., Carter S., Kaur H., Francis S., Tattersall R.S., Snowden J.A. Haemophagocytic Lymphohistiocytosis (HLH) Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)—Time to Reappraise with Modern Diagnostic and Treatment Strategies? Bone Marrow Transpl. 2020;55:307–316. doi: 10.1038/s41409-019-0637-7.
    1. Parisi R., Symmons D.P.M., Griffiths C.E.M., Ashcroft D.M. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J. Investig. Dermatol. 2013;133:377–385. doi: 10.1038/jid.2012.339.
    1. Tsoi L.C., Stuart P.E., Tian C., Gudjonsson J.E., Das S., Zawistowski M., Ellinghaus E., Barker J.N., Chandran V., Dand N., et al. Large Scale Meta-Analysis Characterizes Genetic Architecture for Common Psoriasis Associated Variants. Nat. Commun. 2017;8:15382. doi: 10.1038/ncomms15382.
    1. Liu Y., Helms C., Liao W., Zaba L.C., Duan S., Gardner J., Wise C., Miner A., Malloy M.J., Pullinger C.R., et al. A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. PLoS Genet. 2008;4:e1000041. doi: 10.1371/journal.pgen.1000041.
    1. Armstrong A.W. Psoriasis Provoked or Exacerbated by Medications: Identifying Culprit Drugs. JAMA Dermatol. 2014;150:963. doi: 10.1001/jamadermatol.2014.1019.
    1. Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323:1945. doi: 10.1001/jama.2020.4006.
    1. Ji Y.-Z., Liu S.-R. Koebner Phenomenon Leading to the Formation of New Psoriatic Lesions: Evidences and Mechanisms. Biosci. Rep. 2019;39:BSR20193266. doi: 10.1042/BSR20193266.
    1. Toruniowa B., Jablońska S. Mast Cells in the Initial Stages of Psoriasis. Arch. Dermatol. Res. 1988;280:189–193. doi: 10.1007/BF00513956.
    1. Woźniak E., Owczarczyk-Saczonek A., Placek W. Psychological Stress, Mast Cells, and Psoriasis—Is There Any Relationship? Int. J. Mol. Sci. 2021;22:13252. doi: 10.3390/ijms222413252.
    1. Ortega M.A., García-Montero C., Fraile-Martinez O., Alvarez-Mon M.A., Gómez-Lahoz A.M., Lahera G., Monserrat J., Rodriguez-Jimenez R., Quintero J., Álvarez-Mon M. Immune-Mediated Diseases from the Point of View of Psychoneuroimmunoendocrinology. Biology. 2022;11:973. doi: 10.3390/biology11070973.
    1. Scholzen T., Armstrong C.A., Bunnett N.W., Luger T.A., Olerud J.E., Ansel J.C. Neuropeptides in the Skin: Interactions between the Neuroendocrine and the Skin Immune Systems. Exp. Dermatol. 1998;7:81–96. doi: 10.1111/j.1600-0625.1998.tb00307.x.
    1. Schulze E., Witt M., Fink T., Hofer A., Funk R.H.W. Immunohistochemical Detection of Human Skin Nerve Fibers. Acta Histochem. 1997;99:301–309. doi: 10.1016/S0065-1281(97)80024-4.
    1. Choi J.E., Di Nardo A. Skin Neurogenic Inflammation. Semin. Immunopathol. 2018;40:249–259. doi: 10.1007/s00281-018-0675-z.
    1. Joseph T., Kurian J., Warwick D.J., Friedmann P.S. Unilateral Remission of Psoriasis Following Traumatic Nerve Palsy. Br. J. Dermatol. 2005;152:185–186. doi: 10.1111/j.1365-2133.2005.06330.x.
    1. Zhu T.H., Nakamura M., Farahnik B., Abrouk M., Lee K., Singh R., Gevorgyan A., Koo J., Bhutani T. The Role of the Nervous System in the Pathophysiology of Psoriasis: A Review of Cases of Psoriasis Remission or Improvement Following Denervation Injury. Am. J. Clin. Dermatol. 2016;17:257–263. doi: 10.1007/s40257-016-0183-7.
    1. Kawakami T., Ando T., Kimura M., Wilson B.S., Kawakami Y. Mast Cells in Atopic Dermatitis. Curr. Opin. Immunol. 2009;21:666–678. doi: 10.1016/j.coi.2009.09.006.
    1. Liu F.-T., Goodarzi H., Chen H.-Y. IgE, Mast Cells, and Eosinophils in Atopic Dermatitis. Clinic. Rev. Allergy Immunol. 2011;41:298–310. doi: 10.1007/s12016-011-8252-4.
    1. Kanbe T., Soma Y., Kawa Y., Kashima M., Mizoguchi M. Serum Levels of Soluble Stem Cell Factor and Soluble KIT Are Elevated in Patients with Atopic Dermatitis and Correlate with the Disease Severity. Br. J. Dermatol. 2001;144:1148–1153. doi: 10.1046/j.1365-2133.2001.04224.x.
    1. Oh M., Zhu Z., Yu J., Zheng T. Role of Mast Cells in the Development of Atopic Dermatitis Induced by IL-13. J. Allergy Clin. Immunol. 2012;129:AB36. doi: 10.1016/j.jaci.2011.12.796.
    1. Schwartz H.J., Yunginger J.W., Schwartz L.B. Is Unrecognized Anaphylaxis a Cause of Sudden Unexpected Death? Clin. Exp. Allergy. 1995;25:866–870. doi: 10.1111/j.1365-2222.1995.tb00029.x.
    1. Abdelghany M., Subedi R., Shah S., Kozman H. Kounis Syndrome: A Review Article on Epidemiology, Diagnostic Findings, Management and Complications of Allergic Acute Coronary Syndrome. Int. J. Cardiol. 2017;232:1–4. doi: 10.1016/j.ijcard.2017.01.124.
    1. Forlani D., Scarano G., D’Alleva A., Di Marco M., Paloscia L., Gatta A., Della Valle L., Farinelli A., Lumaca A., Petrarca C., et al. Kounis Syndrome as First Manifestation of Allergic Sensitization. Case Rep. Med. 2019;2019:6317956. doi: 10.1155/2019/6317956.
    1. Kounis N.G. Serum Tryptase Levels and Kounis Syndrome. Int. J. Cardiol. 2007;114:407–408. doi: 10.1016/j.ijcard.2005.11.088.
    1. Fassio F., Losappio L., Antolin-Amerigo D., Peveri S., Pala G., Preziosi D., Massaro I., Giuliani G., Gasperini C., Caminati M., et al. Kounis Syndrome: A Concise Review with Focus on Management. Eur. J. Intern. Med. 2016;30:7–10. doi: 10.1016/j.ejim.2015.12.004.
    1. Malfait F., Francomano C., Byers P., Belmont J., Berglund B., Black J., Bloom L., Bowen J.M., Brady A.F., Burrows N.P., et al. The 2017 International Classification of the Ehlers–Danlos Syndromes. Am. J. Med. Genet. Part C Semin. Med. Genet. 2017;175:8–26. doi: 10.1002/ajmg.c.31552.
    1. Hakim A., Grahame R. Joint Hypermobility. Best Pract. Res. Clin. Rheumatol. 2003;17:989–1004. doi: 10.1016/j.berh.2003.08.001.
    1. Seneviratne S.L., Maitland A., Afrin L. Mast Cell Disorders in Ehlers-Danlos Syndrome. Am. J. Med. Genet. 2017;175:226–236. doi: 10.1002/ajmg.c.31555.
    1. Afrin L.B., Self S., Menk J., Lazarchick J. Characterization of Mast Cell Activation Syndrome. Am. J. Med. Sci. 2017;353:207–215. doi: 10.1016/j.amjms.2016.12.013.
    1. Luzgina N.G., Potapova O.V., Shkurupiy V.A. Structural and Functional Peculiarities of Mast Cells in Undifferentiated Connective Tissue Dysplasia. Bull. Exp. Biol. Med. 2011;150:676–678. doi: 10.1007/s10517-011-1220-4.
    1. Molderings G.J. Transgenerational Transmission of Systemic Mast Cell Activation Disease—Genetic and Epigenetic Features. Transl. Res. 2016;174:86–97. doi: 10.1016/j.trsl.2016.01.001.
    1. Zhang B., Li Q., Shi C., Zhang X. Drug-Induced Pseudoallergy: A Review of the Causes and Mechanisms. Pharmacology. 2018;101:104–110. doi: 10.1159/000479878.
    1. Hamilton M.J. Nonclonal Mast Cell Activation Syndrome. Immunol. Allergy Clin. N. Am. 2018;38:469–481. doi: 10.1016/j.iac.2018.04.002.
    1. Pastorello E.A., Stafylaraki C., Mirone C., Preziosi D., Aversano M.G., Mascheri A., Losappio L.M., Ortolani V., Nichelatti M., Farioli L. Anti-Amoxicillin Immunoglobulin E, Histamine-2 Receptor Antagonist Therapy and Mast Cell Activation Syndrome Are Risk Factors for Amoxicillin Anaphylaxis. Int. Arch. Allergy Immunol. 2015;166:280–286. doi: 10.1159/000380950.
    1. McNeil B.D. Identification of a Mast-Cell-Specific Receptor Crucial for Pseudo-Allergic Drug Reactions. p. 18.
    1. Fica A., Muñoz D., Rojas T., Sanzana C., Muñoz C., Fica A., Muñoz D., Rojas T., Sanzana C., Muñoz C. Penicillin Desensitization in Allergic Pregnant Women with Syphilis. Report of Two Cases. Rev. Médica De Chile. 2020;148:344–348. doi: 10.4067/S0034-98872020000300344.
    1. STD Treatment Guidelines. [(accessed on 4 February 2021)];2015 Available online: .
    1. Janier M., Unemo M., Dupin N., Tiplica G.S., Potočnik M., Patel R. 2020 European Guideline on the Management of Syphilis. J. Eur. Acad Dermatol. Venereol. 2020;35:574–588. doi: 10.1111/jdv.16946.
    1. Pham M.N., Ho H.-E., Desai M. Penicillin Desensitization: Treatment of Syphilis in Pregnancy in Penicillin-Allergic Patients. Ann. Allergy Asthma Immunol. 2017;118:537–541. doi: 10.1016/j.anai.2017.03.013.
    1. Staso P., Leonov A. Drug Desensitization in 17-Year-Old Male with Mast Cell Activation Syndrome, Pneumonia, and Antibiotic Hypersensitivities. AME Case Rep. 2017;1:7. doi: 10.21037/acr.2017.11.03.
    1. Azimi E., Reddy V.B., Lerner E.A. MRGPRX2, Atopic Dermatitis, and Red Man Syndrome. Itch. 2017;2:e5. doi: 10.1097/itx.0000000000000005.
    1. Sivagnanam S., Deleu D. Red Man Syndrome. Crit. Care. 2003;7:119–120. doi: 10.1186/cc1871.
    1. Arroyo-Mercado F., Khudyakov A., Chawla G.S., Cantres-Fonseca O., McFarlane I.M. Red Man Syndrome with Oral Vancomycin: A Case Report. Am. J. Med. Case Rep. 2019;7:16–17. doi: 10.12691/ajmcr-7-1-5.
    1. PRIME PubMed | Red Man Syndrome and Infliximab. [(accessed on 4 February 2021)]. Available online: .
    1. Myers A.L., Gaedigk A., Dai H., James L.P., Jones B.L., Neville K.A. Defining Risk Factors for Red Man Syndrome in Children and Adults. Pediatr. Infect. Dis. J. 2012;31:464–468. doi: 10.1097/INF.0b013e31824e10d7.
    1. Soong L., Sotoodian B., Brassard A. Immediate-Type Infliximab Infusion Reaction Presenting as Purpura. JAAD Case Rep. 2018;4:596–598. doi: 10.1016/j.jdcr.2018.05.015.
    1. Nassau S., Fonacier L. Allergic Contact Dermatitis. Med. Clin. N. Am. 2020;104:61–76. doi: 10.1016/j.mcna.2019.08.012.
    1. Owen J.L., Vakharia P.P., Silverberg J.I. The Role and Diagnosis of Allergic Contact Dermatitis in Patients with Atopic Dermatitis. Am. J. Clin. Dermatol. 2018;19:293–302. doi: 10.1007/s40257-017-0340-7.
    1. Hernandez J.D., Yu M., Sibilano R., Tsai M., Galli S.J. Development of Multiple Features of Antigen-Induced Asthma Pathology in a New Strain of Mast Cell Deficient BALB/c- Kit W-Sh/W-Sh Mice. Lab. Investig. 2020;100:516–526. doi: 10.1038/s41374-019-0354-2.
    1. Morita H., Saito H., Matsumoto K., Nakae S. Regulatory Roles of Mast Cells in Immune Responses. Semin. Immunopathol. 2016;38:623–629. doi: 10.1007/s00281-016-0566-0.
    1. Aroni K., Tsagroni E., Kavantzas N., Patsouris E., Ioannidis E. A Study of the Pathogenesis of Rosacea: How Angiogenesis and Mast Cells May Participate in a Complex Multifactorial Process. Arch. Dermatol. Res. 2008;300:125–131. doi: 10.1007/s00403-007-0816-z.
    1. Wang L., Wang Y.-J., Hao D., Wen X., Du D., He G., Jiang X. The Theranostics Role of Mast Cells in the Pathophysiology of Rosacea. Front. Med. 2019;6:324. doi: 10.3389/fmed.2019.00324.
    1. Muto Y., Wang Z., Vanderberghe M., Two A., Gallo R.L., Di Nardo A. Mast Cells Are Key Mediators of Cathelicidin-Initiated Skin Inflammation in Rosacea. J. Investig. Dermatol. 2014;134:2728–2736. doi: 10.1038/jid.2014.222.
    1. Holmes A.D., Steinhoff M. Integrative Concepts of Rosacea Pathophysiology, Clinical Presentation and New Therapeutics. Exp. Dermatol. 2017;26:659–667. doi: 10.1111/exd.13143.
    1. Ahn C.S., Huang W.W. Rosacea Pathogenesis. Dermatol. Clin. 2018;36:81–86. doi: 10.1016/j.det.2017.11.001.
    1. Systemic Mastocytosis in Adults: 2021 Update on Diagnosis, Risk Stratification and Management—Pardanani—2021—American Journal of Hematology—Wiley Online Library. [(accessed on 20 December 2022)]. Available online: .
    1. Lange M., Hartmann K., Carter M.C., Siebenhaar F., Alvarez-Twose I., Torrado I., Brockow K., Renke J., Irga-Jaworska N., Plata-Nazar K., et al. Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. IJMS. 2021;22:2586. doi: 10.3390/ijms22052586.
    1. Valent P., Akin C., Gleixner K.V., Sperr W.R., Reiter A., Arock M., Triggiani M. Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. IJMS. 2019;20:2976. doi: 10.3390/ijms20122976.
    1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. [(accessed on 20 December 2022)]; Available online: .
    1. Chatterjee A., Ghosh J., Kapur R. Mastocytosis: A Mutated KIT Receptor Induced Myeloproliferative Disorder. Oncotarget. 2015;6:18250–18264. doi: 10.18632/oncotarget.4213.
    1. Valent P., Akin C., Metcalfe D.D. Mastocytosis: 2016 Updated WHO Classification and Novel Emerging Treatment Concepts. Blood. 2017;129:1420–1427. doi: 10.1182/blood-2016-09-731893.
    1. Hartmann K., Escribano L., Grattan C., Brockow K., Carter M.C., Alvarez-Twose I., Matito A., Broesby-Olsen S., Siebenhaar F., Lange M., et al. Cutaneous Manifestations in Patients with Mastocytosis: Consensus Report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J. Allergy Clin. Immunol. 2016;137:35–45. doi: 10.1016/j.jaci.2015.08.034.
    1. Valent P., Horny H.-P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., Marone G., Nuñez R., Akin C., Sotlar K., et al. Diagnostic Criteria and Classification of Mastocytosis: A Consensus Proposal. Leuk. Res. 2001;25:603–625. doi: 10.1016/S0145-2126(01)00038-8.
    1. Brockow K., Plata-Nazar K., Lange M., Nedoszytko B., Niedoszytko M., Valent P. Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis. IJMS. 2021;22:2684. doi: 10.3390/ijms22052684.
    1. Komi D.E.A., Rambasek T., Wöhrl S. Mastocytosis: From a Molecular Point of View. Clinic. Rev. Allergy Immunol. 2018;54:397–411. doi: 10.1007/s12016-017-8619-2.
    1. Méni C., Bruneau J., Georgin-Lavialle S., Le Saché de Peufeilhoux L., Damaj G., Hadj-Rabia S., Fraitag S., Dubreuil P., Hermine O., Bodemer C. Paediatric Mastocytosis: A Systematic Review of 1747 Cases. Br. J. Dermatol. 2015;172:642–651. doi: 10.1111/bjd.13567.
    1. Barnes M., Van L., DeLong L., Lawley L.P. Severity of Cutaneous Findings Predict the Presence of Systemic Symptoms in Pediatric Maculopapular Cutaneous Mastocytosis. Pediatr. Dermatol. 2014;31:271–275. doi: 10.1111/pde.12291.
    1. Krečak I., Karaman I., Jakelić S. Darier’s Sign. Eur. J. Intern. Med. 2022;97:97–98. doi: 10.1016/j.ejim.2022.01.004.
    1. Kwiatkowska D., Reich A. Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis. Acta Derm. Venereol. 2021;101:350. doi: 10.2340/actadv.v101.350.
    1. Reich A., Szepietowski J.C. Diagnostic Procedures of Itch. In: Szepietowski J., Weisshaar E., editors. Current Problems in Dermatology. Volume 50. S. Karger AG; Basel, Switzerland: 2016. pp. 24–28.
    1. Carter M.C., Metcalfe D.D., Komarow H.D. Mastocytosis. Immunol. Allergy Clin. N. Am. 2014;34:181–196. doi: 10.1016/j.iac.2013.09.001.
    1. Mast Cells, Glia and Neuroinflammation: Partners in Crime?—PMC. [(accessed on 20 December 2022)]; Available online:
    1. Pentland A.P., Mahoney M., Jacobs S.C., Holtzman M.J. Enhanced Prostaglandin Synthesis after Ultraviolet Injury Is Mediated by Endogenous Histamine Stimulation. A Mechanism for Irradiation Erythema. J. Clin. Investig. 1990;86:566–574. doi: 10.1172/JCI114746.
    1. Matito A., Azaña J.M., Torrelo A., Alvarez-Twose I. Cutaneous Mastocytosis in Adults and Children. Immunol. Allergy Clin. N. Am. 2018;38:351–363. doi: 10.1016/j.iac.2018.04.001.
    1. Kleewein K., Lang R., Diem A., Vogel T., Pohla-Gubo G., Bauer J.W., Hintner H., Laimer M. Diffuse Cutaneous Mastocytosis Masquerading as Epidermolysis Bullosa. Pediatr. Dermatol. 2011;28:720–725. doi: 10.1111/j.1525-1470.2011.01479.x.
    1. Lange M., Niedoszytko M., Nedoszytko B., Łata J., Trzeciak M., Biernat W. Diffuse Cutaneous Mastocytosis: Analysis of 10 Cases and a Brief Review of the Literature: Diffuse Cutaneous Mastocytosis. J. Eur. Acad. Dermatol. Venereol. 2011;26:1565–1571. doi: 10.1111/j.1468-3083.2011.04350.x.
    1. Lange M., Niedoszytko M., Renke J., Gleń J., Nedoszytko B. Clinical Aspects of Paediatric Mastocytosis: A Review of 101 Cases: Clinical Aspects of Paediatric Mastocytosis. J. Eur. Acad. Dermatol. Venereol. 2013;27:97–102. doi: 10.1111/j.1468-3083.2011.04365.x.
    1. Brockow K., Ring J., Alvarez-Twose I., Orfao A., Escribano L. Extensive Blistering Is a Predictor for Severe Complications in Children with Mastocytosis. Allergy. 2012;67:1323–1324. doi: 10.1111/all.12013.
    1. Hoermann G., Cerny-Reiterer S., Perné A., Klauser M., Hoetzenecker K., Klein K., Müllauer L., Gröger M., Nijman S.M.B., Klepetko W., et al. Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis. Am. J. Pathol. 2011;178:2344–2356. doi: 10.1016/j.ajpath.2011.01.020.
    1. Metcalfe D.D. Mast Cells and Mastocytosis. Blood. 2008;112:946–956. doi: 10.1182/blood-2007-11-078097.
    1. Valent P. KIT D816V and the Cytokine Storm in Mastocytosis: Production and Role of Interleukin-6. Haematologica. 2020;105:5–6. doi: 10.3324/haematol.2019.234864.
    1. Tobío A., Bandara G., Morris D.A., Kim D.-K., O’Connell M.P., Komarow H.D., Carter M.C., Smrz D., Metcalfe D.D., Olivera A. Oncogenic D816V-KIT Signaling in Mast Cells Causes Persistent IL-6 Production. Haematologica. 2020;105:124–135. doi: 10.3324/haematol.2018.212126.
    1. Greiner G., Witzeneder N., Berger A., Schmetterer K., Eisenwort G., Schiefer A.-I., Roos S., Popow-Kraupp T., Müllauer L., Zuber J., et al. CCL2 Is a KIT D816V–Dependent Modulator of the Bone Marrow Microenvironment in Systemic Mastocytosis. Blood. 2017;129:371–382. doi: 10.1182/blood-2016-09-739003.
    1. Ahn Y.M., Hong G.U., Kim S.H., Lee H.J., Baek H.S., Kim M.N., Park K.Y., Ro J.Y. Transglutaminase 2 Expressed in Mast Cells Recruited into Skin or Bone Marrow Induces the Development of Pediatric Mastocytosis. Pediatr. Allergy Immunol. 2015;26:438–445. doi: 10.1111/pai.12403.
    1. Lauritano D., Ronconi G., Caraffa A., Enrica Gallenga C., Kritas S.K., Di Emidio P., Martinotti S., Tetè G., Ross R., Conti P. New Aspect of Allergic Contact Dermatitis, an Inflammatory Skin Disorder Mediated by Mast Cells: Can IL-38 Help? Med. Hypotheses. 2020;139:109687. doi: 10.1016/j.mehy.2020.109687.
    1. Ayasse M.T., Buddenkotte J., Alam M., Steinhoff M. Role of Neuroimmune Circuits and Pruritus in Psoriasis. Exp. Dermatol. 2020;29:414–426. doi: 10.1111/exd.14071.
    1. Voss M., Kotrba J., Gaffal E., Katsoulis-Dimitriou K., Dudeck A. Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation? Int. J. Mol. Sci. 2021;22:4589. doi: 10.3390/ijms22094589.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir